Skip navigation
Agenda

State-by-State Requirements and Reporting • Current and Future Policy Initiatives • Operational Best Practices

March 25-26, 2019
  • Philadelphia, PA

Agenda

Want more agenda details? Download the brochure.
PRE-CONFERENCE WORKSHOP | MONDAY, MARCH 25, 2019

Medicare Drug Pricing and Reimbursement — Deep Dive into the Emerging International Pricing Model

12:30

Pre-Conference Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:
This pre-conference workshop explores the factors that drug pricing transparency encompasses by breaking down the multifaceted counterparts that affect industry.

I.Assess the Status of Copays and Rebates and their Role in the Drug Pricing System
II.Manage Medicare Part B and Identify Potential Changes in the Market

Workshop Leader:

Trevor L. Wear
Partner
Sidley Austin LLP

There will be a 30 minute networking and refreshment break at 3:00

5:00

Close of Workshop

MAIN CONFERENCE
THURSDAY, MARCH 26, 2019

7:30

Conference Registration and Continental Breakfast

8:15

Chairperson’s Opening Remarks

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

8:30

KEYNOTE ADDRESSState Drug Pricing Reporting and Requirements Landscape

John A. Murphy III
Deputy General Counsel
Biotechnology Innovation Organization (BIO)

9:15

Federal Initiatives in Regards to Transparency — Downstream Effects for States

Sarah diFrancesca
Partner
Cooley LLP

10:00

Networking and Refreshment Break

State-by-State Analysis Showcase

This state-by-state analysis showcase shines a spotlight on states that have established regulations and/or guidance. Gain an understanding of current requirements and reporting regulations that will affect drug pricing transparency in 2019 through deep dives led by industry experts.

10:30

Update on California SB-17 — A Leader in Drug Pricing Transparency Law

James Kim
Attorney
McDermott, Will & Emery LLP

11:00

Oregon HB-4005 Implementation and Enforcement

Trevor L. Wear
Partner
Sidley Austin LLP

11:30

Status Report on Nevada’s SB-539

David Gibbons
Associate
Hyman,Phelps & McNamara P.C.

12:00

Networking Luncheon

1:00

PANEL DISCUSSIONKeeping a Pulse on New Legislation — Policy Considerations for State Drug Pricing Transparency Laws

PANELISTS:

Joanne Chan
Assistant General Counsel
Pharmaceutical Research and Manufacturers
of America (PhRMA)

Kendra Martello
Senior Director, Public Policy, Government Affairs and Public Policy
Mallinckrodt Pharmaceuticals

Amie Phillips Pablo
Director, Ethics and Compliance
Novo Nordisk

2:00

International Health Systems — Why it is Getting Harder to Prove Medicines Are Worth It

Prasun Subedi
Senior Director, Patient and Health Impact
Pfizer Inc

Keren Tenenbaum
Assistant General Counsel
Pfizer Inc

2:45

Networking and Refreshment Break

3:15

Analyze Organizational Structure— Identify and Optimize Drug Pricing Transparency for Internal Efficiency

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

William Harris
Assistant General Counsel, US Market Access
Sanofi

4:00

The Impact of Lowering a Drug Price in an Organization

Speaker TBA

4:45

Industry Talk — Operational Best Practices for Compliance

CONVERSATION CONTRIBUTORS:

Brian Bohnenkamp
Partner
King & Spalding LLP

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

Amie Phillips Pablo
Director, Ethics and Compliance
Novo Nordisk

5:30

Close of Conference

Agenda

Want more agenda details? Download the brochure.

Want more agenda details? Download the brochure.
PRE-CONFERENCE WORKSHOP | MONDAY, MARCH 25, 2019

Medicare Drug Pricing and Reimbursement — Deep Dive into the Emerging International Pricing Model

12:30

Pre-Conference Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:
This pre-conference workshop explores the factors that drug pricing transparency encompasses by breaking down the multifaceted counterparts that affect industry.

I.Assess the Status of Copays and Rebates and their Role in the Drug Pricing System
II.Manage Medicare Part B and Identify Potential Changes in the Market

Workshop Leader:

Trevor L. Wear
Partner
Sidley Austin LLP

There will be a 30 minute networking and refreshment break at 3:00

5:00

Close of Workshop

MAIN CONFERENCE
THURSDAY, MARCH 26, 2019

7:30

Conference Registration and Continental Breakfast

8:15

Chairperson’s Opening Remarks

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

8:30

KEYNOTE ADDRESSState Drug Pricing Reporting and Requirements Landscape

John A. Murphy III
Deputy General Counsel
Biotechnology Innovation Organization (BIO)

9:15

Federal Initiatives in Regards to Transparency — Downstream Effects for States

Sarah diFrancesca
Partner
Cooley LLP

10:00

Networking and Refreshment Break

State-by-State Analysis Showcase

This state-by-state analysis showcase shines a spotlight on states that have established regulations and/or guidance. Gain an understanding of current requirements and reporting regulations that will affect drug pricing transparency in 2019 through deep dives led by industry experts.

10:30

Update on California SB-17 — A Leader in Drug Pricing Transparency Law

James Kim
Attorney
McDermott, Will & Emery LLP

11:00

Oregon HB-4005 Implementation and Enforcement

Trevor L. Wear
Partner
Sidley Austin LLP

11:30

Status Report on Nevada’s SB-539

David Gibbons
Associate
Hyman,Phelps & McNamara P.C.

12:00

Networking Luncheon

1:00

PANEL DISCUSSIONKeeping a Pulse on New Legislation — Policy Considerations for State Drug Pricing Transparency Laws

PANELISTS:

Joanne Chan
Assistant General Counsel
Pharmaceutical Research and Manufacturers
of America (PhRMA)

Kendra Martello
Senior Director, Public Policy, Government Affairs and Public Policy
Mallinckrodt Pharmaceuticals

Amie Phillips Pablo
Director, Ethics and Compliance
Novo Nordisk

2:00

International Health Systems — Why it is Getting Harder to Prove Medicines Are Worth It

Prasun Subedi
Senior Director, Patient and Health Impact
Pfizer Inc

Keren Tenenbaum
Assistant General Counsel
Pfizer Inc

2:45

Networking and Refreshment Break

3:15

Analyze Organizational Structure— Identify and Optimize Drug Pricing Transparency for Internal Efficiency

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

William Harris
Assistant General Counsel, US Market Access
Sanofi

4:00

The Impact of Lowering a Drug Price in an Organization

Speaker TBA

4:45

Industry Talk — Operational Best Practices for Compliance

CONVERSATION CONTRIBUTORS:

Brian Bohnenkamp
Partner
King & Spalding LLP

Debbie A. Walters-Francique
Vice President, Assistant General Counsel
Pfizer Inc

Amie Phillips Pablo
Director, Ethics and Compliance
Novo Nordisk

5:30

Close of Conference